From the FDA Drug Label
Discontinue OZEMPIC in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide [see Use in Specific Populations (8.1)]. Females and Males of Reproductive Potential: Discontinue OZEMPIC in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide (8.3).
It is advised to wait at least 2 months after discontinuing GLP-1 agonists, such as semaglutide, before attempting pregnancy due to the long washout period for semaglutide 1 1.
- The long washout period is the reason for this recommendation.
- This advice is specifically for women planning pregnancy.
From the Research
It is recommended to discontinue GLP-1 agonists like liraglutide (Victoza) and semaglutide (Ozempic) at least 4 weeks before attempting pregnancy, as suggested by the most recent study 2. This waiting period allows the medication to be cleared from the body and minimizes potential risks to the fetus. The recommendation stems from limited safety data on the use of these medications during pregnancy and concerns about potential effects on fetal development.
Key Considerations
- GLP-1 agonists are not approved for use during pregnancy, and animal studies have shown some adverse reproductive effects at high doses 3.
- Women taking these medications for diabetes management should work with their healthcare provider to transition to pregnancy-safe alternatives like insulin before conception.
- Those using GLP-1 agonists for weight management should discuss a pregnancy-appropriate weight management plan with their healthcare provider.
- Establishing good glycemic control through other means before conception is important for reducing pregnancy complications and improving outcomes for both mother and baby.
Evidence Summary
- A recent study published in 2023 found no adverse pregnancy or neonatal outcomes in patients who conceived while on a GLP-1 receptor agonist, but highlighted the need for more data to guide decision-making regarding timing of discontinuation 2.
- Another study published in 2024 found that periconceptional use of GLP-1 receptor agonists was not associated with a large increased risk of major congenital malformations, but emphasized the need for continuous monitoring and more precise estimates as data accumulate 4.
- The American Journal of Obstetrics and Gynecology published a review in 2025 stating that there is currently little data for clinicians to use in counseling patients in cases of accidental periconceptional exposure to GLP-1 receptor agonists, and recommended that all patients use contraception to prevent unintended pregnancy while taking these medications 5.